Literature DB >> 15989956

ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.

Delin Chen1, Ning Kon, Muyang Li, Wenzhu Zhang, Jun Qin, Wei Gu.   

Abstract

Although the importance of the ARF tumor suppressor in p53 regulation is well established, numerous studies indicate that ARF also suppresses cell growth in a p53/Mdm2-independent manner. To understand the mechanism of ARF-mediated tumor suppression, we identified a ubiquitin ligase, ARF-BP1, as a key factor associated with ARF in vivo. ARF-BP1 harbors a signature HECT motif, and its ubiquitin ligase activity is inhibited by ARF. Notably, inactivation of ARF-BP1, but not Mdm2, suppresses the growth of p53 null cells in a manner reminiscent of ARF induction. Surprisingly, in p53 wild-type cells, ARF-BP1 directly binds and ubiquitinates p53, and inactivation of endogenous ARF-BP1 is crucial for ARF-mediated p53 stabilization. Thus, our study modifies the current view of ARF-mediated p53 activation and reveals that ARF-BP1 is a critical mediator of both the p53-independent and p53-dependent tumor suppressor functions of ARF. As such, ARF-BP1 may serve as a potential target for therapeutic intervention in tumors regardless of p53 status.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15989956     DOI: 10.1016/j.cell.2005.03.037

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  232 in total

1.  Expression of the novel human gene, UBE2Q1, in breast tumors.

Authors:  Atefeh Seghatoleslam; Mohsen Nikseresht; Sayed Mohammad Shafiee; Ahmad Monabati; Mohammad Mehdi Namavari; Abdolrassul Talei; Akbar Safaei; Ali Akbar Owji
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

Review 2.  Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development.

Authors:  W-L Yang; X Zhang; H-K Lin
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

3.  Differential effects on p53-mediated cell cycle arrest vs. apoptosis by p90.

Authors:  Chao Dai; Yi Tang; Sung Yun Jung; Jun Qin; Stuart A Aaronson; Wei Gu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

4.  Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2.

Authors:  Jing Nie; Ping Xie; Lin Liu; Guichun Xing; Zhijie Chang; Yuxin Yin; Chunyan Tian; Fuchu He; Lingqiang Zhang
Journal:  J Biol Chem       Date:  2010-05-18       Impact factor: 5.157

5.  E3 ligases Arf-bp1 and Pam mediate lithium-stimulated degradation of the circadian heme receptor Rev-erb alpha.

Authors:  Lei Yin; Shree Joshi; Nan Wu; Xin Tong; Mitchell A Lazar
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

6.  E3 ubiquitin ligase Mule ubiquitinates Miz1 and is required for TNFalpha-induced JNK activation.

Authors:  Yi Yang; HanhChi Do; Xuejun Tian; Chaozheng Zhang; Xinyuan Liu; Laura A Dada; Jacob I Sznajder; Jing Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

7.  Substrate phosphorylation and feedback regulation in JFK-promoted p53 destabilization.

Authors:  Luyang Sun; Lei Shi; Feng Wang; Peiwei Huangyang; Wenzhe Si; Jie Yang; Zhi Yao; Yongfeng Shang
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

8.  Transcriptional regulation of HIV-1 gene expression by p53.

Authors:  Ruma Mukerjee; Pier Paolo Claudio; J Robert Chang; Luis Del Valle; Bassel E Sawaya
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

9.  Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.

Authors:  Jonathan Shloush; John E Vlassov; Ian Engson; Shili Duan; Vivian Saridakis; Sirano Dhe-Paganon; Brian Raught; Yi Sheng; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

10.  p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest.

Authors:  Christian J Braun; Xin Zhang; Irina Savelyeva; Sonja Wolff; Ute M Moll; Troels Schepeler; Torben F Ørntoft; Claus L Andersen; Matthias Dobbelstein
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.